Tirzepatide for Weight Loss: Results, Timeline and Before-and-After

SURMOUNT-1 (Jastreboff et al., NEJM 2022) enrolled 2,539 adults with obesity or overweight who did not have diabetes.

Mean weight change at 72 weeks was -15.0% on the 5 mg dose, -19.5% on 10 mg and -20.9% on 15 mg, against -3.1% on placebo.

Responder shares tell the same story from another angle: 85–91% of participants lost at least 5% of their body weight by week 72, and 50% of the 10 mg group and 57% of the 15 mg group lost 20% or more, compared with 3% on placebo.

Adults with type 2 diabetes lost less in the trial that enrolled them (the Zepbound label's Study 2, SURMOUNT-2): -12.8% on 10 mg and -14.7% on 15 mg at 72 weeks, versus -3.2% on placebo.

Two qualifiers sit over all of these numbers.

They are trial means at specific doses, not individual results, and the trials paired tirzepatide with structured lifestyle counseling — the same context the label assumes, because Zepbound is approved for use with a reduced-calorie diet and increased physical activity.

The honest answer first: we could not find a Zepbound label or a published tirzepatide trial that gives month-by-month weight figures in quotable text — the labels show the weight-change curve only as charts.

So a table promising a set figure for every month is not coming from the label or the trials we checked.

What the label does timestamp is the dose schedule.

Zepbound starts at 2.5 mg once weekly for 4 weeks — a dose the label calls a starter dose only, not a maintenance dose — then moves to 5 mg, and from there increases in 2.5 mg steps, with at least 4 weeks on each dose before the next increase.

For weight reduction, the label's maintenance doses are 5 mg, 10 mg or 15 mg once weekly.

The trials were scored at the far end: weight reduction was assessed after 72 weeks of treatment, with at least 52 weeks at a maintenance dose, and the loss accrued gradually across that period rather than in fixed monthly blocks.

The trial averages hide a spread, and a slower result sits inside it: even in SURMOUNT-1, 50% of the 10 mg group and 57% of the 15 mg group lost 20% or more by week 72, which means the other participants in those groups lost less than that.

Dose is the first thing the data point to.

The -20.9% headline comes from the 15 mg group; the 5 mg group averaged -15.0%.

And in the first 4 weeks you are, by label design, on 2.5 mg — the starter dose the label does not count as a maintenance dose — so the earliest stretch is titration, not the dosing the trial averages came from.

Type 2 diabetes changed the numbers too: average loss at 72 weeks was smaller in adults with type 2 diabetes (-12.8% to -14.7% on the two higher doses) than in SURMOUNT-1, which excluded diabetes.

Context matters as well.

The averages come from programs that added structured lifestyle counseling, and the approved use is tirzepatide with a reduced-calorie diet and increased physical activity — the trials were not measuring the drug alone.

On plateaus, the honest line is that we found no label or trial statement that explains why one person's weight stalls while a group average keeps moving; the published data report averages at set weeks.

If your weight has stopped changing on your current dose, that is a specific question for the prescriber managing your program.

The clearest data come from SURMOUNT-4 (Aronne et al., JAMA 2024), which followed 670 adults.

Participants first took open-label tirzepatide for 36 weeks, losing 20.9% of their body weight on average, and then either continued tirzepatide or switched to placebo through week 88.

The two groups moved in opposite directions: from week 36 to week 88, those who switched to placebo regained 14.0% of body weight on average, while those who kept taking tirzepatide lost a further 5.5%.

Measured across the whole study, week 0 to week 88, total loss was 25.3% with continued tirzepatide versus 9.9% after switching to placebo.

This is one withdrawal trial, so it shows a direction rather than anyone's personal outcome.

The label's own framing is long term: Zepbound is approved, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term.

How long to stay on any medication is a decision for you and your prescriber.

Search tirzepatide reviews or tirzepatide before-and-after threads and you will find personal numbers in every direction.

We do not quote individual reviews on this page, because there is no way to verify the dose, the duration, the diabetes status or the photography behind any of them.

The verifiable picture is the spread inside the trial itself: 85–91% of SURMOUNT-1 participants lost at least 5% of their body weight, while 50% on 10 mg and 57% on 15 mg lost 20% or more — real participants in the same trial finished 72 weeks with noticeably different results.

The trial records also show what the outcome traveled with: dose group, diabetes status, a structured lifestyle program and a full 72 weeks of measurement.

A before-and-after photo shows one person's result under conditions you cannot see.

It is not a preview of your result.

Zepbound is prescription-only: it requires a valid prescription from a licensed prescriber, and the FDA tells patients to fill prescriptions at state-licensed pharmacies.

Whether a nurse practitioner can prescribe it independently depends on your state; our page on who can prescribe GLP-1s walks through the rules.

Ask any program what it actually dispenses.

Compounded tirzepatide is a different product from brand-name Zepbound: FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing, and its list of telehealth red flags includes claiming a compounded drug is the same as an FDA-approved one.

The label's own risks and side-effect rates are covered on our tirzepatide side-effects page, and the full treatment picture — cost per month, dosing and prescribing — is in our tirzepatide guide; our semaglutide vs tirzepatide comparison puts the two drugs side by side.